Taiwan

Taiwan

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
7.85 (7.50 - 8.19) 2019 Modelled IHME
7.83 (7.48 - 8.15) 2018 Modelled IHME
7.82 (7.44 - 8.20) 2017 Modelled IHME
8 (7.68 - 8.35) 2016 Modelled IHME
8.22 (7.88 - 8.58) 2015 Modelled IHME
8.32 (7.99 - 8.66) 2014 Modelled IHME
8.39 (8.07 - 8.74) 2013 Modelled IHME
8.45 (8.13 - 8.80) 2012 Modelled IHME
8.51 (8.17 - 8.87) 2011 Modelled IHME
8.56 (8.20 - 8.96) 2010 Modelled IHME
8.62 (8.29 - 9.02) 2009 Modelled IHME
8.67 (8.35 - 9.05) 2008 Modelled IHME
8.72 (8.41 - 9.09) 2007 Modelled IHME
8.77 (8.43 - 9.16) 2006 Modelled IHME
8.83 (8.46 - 9.27) 2005 Modelled IHME
8.89 (8.53 - 9.30) 2004 Modelled IHME
8.95 (8.59 - 9.36) 2003 Modelled IHME
9.02 (8.65 - 9.41) 2002 Modelled IHME
9.1 (8.70 - 9.49) 2001 Modelled IHME
9.18 (8.73 - 9.60) 2000 Modelled IHME
9.28 (8.88 - 9.66) 1999 Modelled IHME
9.39 (9.01 - 9.78) 1998 Modelled IHME
9.51 (9.13 - 9.90) 1997 Modelled IHME
9.63 (9.24 - 10.06) 1996 Modelled IHME
9.73 (9.31 - 10.19) 1995 Modelled IHME
9.83 (9.43 - 10.26) 1994 Modelled IHME
9.93 (9.53 - 10.35) 1993 Modelled IHME
10.02 (9.61 - 10.45) 1992 Modelled IHME
10.11 (9.67 - 10.56) 1991 Modelled IHME
10.2 (9.71 - 10.67) 1990 Modelled IHME
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.16 (0.13 - 0.18) 2019 Modelled IHME
0.16 (0.14 - 0.18) 2018 Modelled IHME
0.16 (0.14 - 0.19) 2017 Modelled IHME
0.16 (0.14 - 0.19) 2016 Modelled IHME
0.17 (0.14 - 0.19) 2015 Modelled IHME
0.17 (0.14 - 0.19) 2014 Modelled IHME
0.17 (0.14 - 0.19) 2013 Modelled IHME
0.17 (0.15 - 0.20) 2012 Modelled IHME
0.17 (0.15 - 0.20) 2011 Modelled IHME
0.18 (0.15 - 0.21) 2010 Modelled IHME
0.18 (0.16 - 0.21) 2009 Modelled IHME
0.19 (0.16 - 0.22) 2008 Modelled IHME
0.2 (0.17 - 0.23) 2007 Modelled IHME
0.21 (0.18 - 0.24) 2006 Modelled IHME
0.22 (0.19 - 0.25) 2005 Modelled IHME
0.23 (0.20 - 0.26) 2004 Modelled IHME
0.24 (0.21 - 0.28) 2003 Modelled IHME
0.26 (0.22 - 0.30) 2002 Modelled IHME
0.28 (0.24 - 0.32) 2001 Modelled IHME
0.3 (0.25 - 0.35) 2000 Modelled IHME
0.32 (0.27 - 0.37) 1999 Modelled IHME
0.35 (0.30 - 0.40) 1998 Modelled IHME
0.37 (0.32 - 0.43) 1997 Modelled IHME
0.41 (0.35 - 0.47) 1996 Modelled IHME
0.45 (0.39 - 0.52) 1995 Modelled IHME
0.49 (0.42 - 0.57) 1994 Modelled IHME
0.55 (0.47 - 0.64) 1993 Modelled IHME
0.61 (0.53 - 0.71) 1992 Modelled IHME
0.68 (0.59 - 0.79) 1991 Modelled IHME
0.76 (0.65 - 0.88) 1990 Modelled IHME
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
42 (34 - 51) 2019 Modelled IHME
41 (34 - 50) 2018 Modelled IHME
41 (34 - 50) 2017 Modelled IHME
41 (33 - 49) 2016 Modelled IHME
41 (33 - 48) 2015 Modelled IHME
41 (34 - 48) 2014 Modelled IHME
40 (33 - 48) 2013 Modelled IHME
40 (33 - 47) 2012 Modelled IHME
40 (34 - 47) 2011 Modelled IHME
40 (34 - 47) 2010 Modelled IHME
41 (34 - 47) 2009 Modelled IHME
41 (35 - 48) 2008 Modelled IHME
42 (36 - 49) 2007 Modelled IHME
43 (37 - 50) 2006 Modelled IHME
43 (37 - 50) 2005 Modelled IHME
44 (37 - 50) 2004 Modelled IHME
44 (37 - 50) 2003 Modelled IHME
44 (38 - 51) 2002 Modelled IHME
45 (39 - 51) 2001 Modelled IHME
45 (39 - 52) 2000 Modelled IHME
46 (40 - 53) 1999 Modelled IHME
47 (41 - 54) 1998 Modelled IHME
49 (42 - 55) 1997 Modelled IHME
50 (43 - 56) 1996 Modelled IHME
51 (44 - 57) 1995 Modelled IHME
52 (45 - 59) 1994 Modelled IHME
53 (46 - 60) 1993 Modelled IHME
54 (46 - 61) 1992 Modelled IHME
55 (47 - 62) 1991 Modelled IHME
55 (47 - 64) 1990 Modelled IHME
Showing out of
Show more
Technical notes
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes
Year of birth dose introduction
1992
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2025
HCV testing policy
Universal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.92 (1.57 - 2.39) 2019 Modelled IHME
1.92 (1.58 - 2.35) 2018 Modelled IHME
1.93 (1.57 - 2.38) 2017 Modelled IHME
1.95 (1.61 - 2.39) 2016 Modelled IHME
1.98 (1.62 - 2.44) 2015 Modelled IHME
2.1 (1.74 - 2.54) 2014 Modelled IHME
2.33 (1.96 - 2.76) 2013 Modelled IHME
2.61 (2.22 - 3.06) 2012 Modelled IHME
2.9 (2.48 - 3.36) 2011 Modelled IHME
3.13 (2.68 - 3.61) 2010 Modelled IHME
3.33 (2.84 - 3.83) 2009 Modelled IHME
3.53 (3.02 - 4.05) 2008 Modelled IHME
3.71 (3.20 - 4.27) 2007 Modelled IHME
3.85 (3.32 - 4.44) 2006 Modelled IHME
3.9 (3.36 - 4.53) 2005 Modelled IHME
3.9 (3.37 - 4.51) 2004 Modelled IHME
3.89 (3.37 - 4.50) 2003 Modelled IHME
3.89 (3.36 - 4.49) 2002 Modelled IHME
3.88 (3.35 - 4.48) 2001 Modelled IHME
3.87 (3.34 - 4.46) 2000 Modelled IHME
3.83 (3.31 - 4.41) 1999 Modelled IHME
3.74 (3.23 - 4.30) 1998 Modelled IHME
3.63 (3.14 - 4.16) 1997 Modelled IHME
3.51 (3.04 - 4.03) 1996 Modelled IHME
3.41 (2.94 - 3.94) 1995 Modelled IHME
3.34 (2.87 - 3.85) 1994 Modelled IHME
3.26 (2.80 - 3.76) 1993 Modelled IHME
3.18 (2.73 - 3.69) 1992 Modelled IHME
3.11 (2.64 - 3.64) 1991 Modelled IHME
3.05 (2.57 - 3.61) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
4.4 (2.50 - 6.30) 2014 Modelled Gower et al, 2014
People who inject drugs (PWID)
Download
Value (%) Year Type Source
91 (89.50 - 92.40) 2011 Modelled Degenhardt L et al, 2017

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
37 (28 - 45) 2019 Modelled IHME
37 (29 - 45) 2018 Modelled IHME
37 (30 - 45) 2017 Modelled IHME
38 (30 - 45) 2016 Modelled IHME
38 (30 - 45) 2015 Modelled IHME
38 (30 - 45) 2014 Modelled IHME
38 (31 - 45) 2013 Modelled IHME
38 (31 - 45) 2012 Modelled IHME
38 (31 - 45) 2011 Modelled IHME
38 (31 - 45) 2010 Modelled IHME
38 (31 - 44) 2009 Modelled IHME
37 (30 - 43) 2008 Modelled IHME
36 (29 - 43) 2007 Modelled IHME
36 (29 - 42) 2006 Modelled IHME
35 (28 - 41) 2005 Modelled IHME
35 (28 - 41) 2004 Modelled IHME
35 (28 - 41) 2003 Modelled IHME
34 (28 - 40) 2002 Modelled IHME
33 (27 - 39) 2001 Modelled IHME
33 (26 - 39) 2000 Modelled IHME
32 (26 - 38) 1999 Modelled IHME
31 (25 - 37) 1998 Modelled IHME
30 (24 - 36) 1997 Modelled IHME
29 (23 - 35) 1996 Modelled IHME
28 (22 - 35) 1995 Modelled IHME
27 (21 - 34) 1994 Modelled IHME
27 (21 - 33) 1993 Modelled IHME
26 (20 - 33) 1992 Modelled IHME
26 (19 - 32) 1991 Modelled IHME
25 (18 - 32) 1990 Modelled IHME
Showing out of
Show more
Technical notes
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes
Year of birth dose introduction
1992
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2025
HCV testing policy
Universal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No

Overview

HBV elimination goal
HCV elimination goal
Year of goal
2025

Prevalence (national)

Modelled

HBV (HBsAg+)
7.85 (%)
2019
(7.5 - 8.19(%))
IHME
HCV (RNA/cAg+)
1.92 (%)
2019
(1.57 - 2.39(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
3,679
2019
(2,713 - 4,947)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
2,327
2019
(1,708 - 3,124)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.16 (%)
2019, latest modelled
(0.13 - 0.18(%))
IHME

Prevalence PWID

HCV
91 (%)
2011, latest modelled
(89.50 - 92.40(%))
Degenhardt L et al, 2017

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines